The Clinical Trials Support Resource (CTSR) supports clinical trials through administrative support, information technology, and regulatory affairs. The CTSR complements the Protocol Review and Monitoring System (PRMS) and encourages the advancement of cancer research. CTSR is supported by 49 staff members under the direction of Dr. Maurie Markman, Vice President for Clinical Research. Administrative Support within the CTSR supplies infrastructure for the day-to-day operational management of the clinical research program. This includes central management and oversight functions for coordinating and reporting on clinical research protocols. Regulatory Affairs Support from the CTSR is dedicated to servicing the needs of the clinical investigators and adhering to the highest standards of clinical research compliance with local, state and federal regulations. CTSR provides centralized support for the submission, review, approval, activation, modification, continuing review and termination of protocols involving human subjects research. This includes the staffing of the Institutional Review Board (IRB) and the Data Monitoring Committee (DMC). The staff coordinates and maintains regulatory data for tracking the life cycle of the research protocols. These regulatory documents are part of the master protocol file in CTSR and are in both electronic and paper media. Information Technology Support within the CTSR comes from the Research Applications Information System (RAIS) staff who support the development and maintenance of centralized databases for research-related regulatory and clinical data. The Protocol Data Management System (PDMS) and the Clinical Oncology Research system (CORe), provide structure and tools to manage and share clinical research data. The Protocol Document On-Line (POOL) database supports and facilitates the complete life cycle of the protocol document, including the submission, review and approval processes performed by the Clinical Research Committee and Institutional Review Board (IRB) meetings. During the last fiscal year, the funds used to support the CTSR salaries were $475,485 (25%) from the Cancer Center Support Grant (CCSG), $172,163 (9%) from user fees and $1,295,771 (66%) from the Institution. In the next award cycle, the level of support from the CCSG, the user fees and the institution is projected to be closer to 22% and 12% and 66%, respectively. The CTSR supported 2739 protocols from 599 cancer center members, of whom 81% hold peer-reviewed funding. During the last several years, the number of new protocols managed by CTSR has remained constant. Protocols that do not meet the UTMDACC scientific standards are typically withdrawn from submission and review. While the volume of protocols has not increased, the oversight of clinical research has become increasingly complex and time-consuming due to evolving regulatory requirements and the current research climate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144404
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$696,935
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Abaza, Yasmin; M Kantarjian, Hagop; Faderl, Stefan et al. (2018) Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93:91-99
Ok, Chi Young; Loghavi, Sanam; Sui, Dawen et al. (2018) Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica :
Ajani, Jaffer A; Estrella, Jeannelyn S; Chen, Qiongrong et al. (2018) Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer 118:52-61
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Khan, Maliha; Muzzafar, Tariq; Kantarjian, Hagop et al. (2018) Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97:1183-1191
Somaiah, Neeta; Beird, Hannah C; Barbo, Andrea et al. (2018) Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9:19891-19899
Sandulache, Vlad C; Michikawa, Chieko; Kataria, Pranav et al. (2018) High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res 24:1727-1733
Puli, Oorvashi Roy; Danysh, Brian P; McBeath, Elena et al. (2018) The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia 20:1121-1134
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360

Showing the most recent 10 out of 12418 publications